Literature DB >> 12030738

Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels.

B Yang1, D F Yao, M Ohuchi, M Ide, M Yano, Y Okumura, H Kido.   

Abstract

The protective effect of ambroxol, a mucolytic agent which has antioxidant properties and stimulates the release of pulmonary surfactant, against influenza-virus proliferation in the airway was investigated in mice. Ambroxol or the vehicle was administered intraperitoneally twice a day for 5-7 days to mice shortly after intranasal infection with a lethal dose of influenza A/Aichi/68 (H3N2) virus, and the survival rate, virus titre and levels of factors regulating virus proliferation in the airway fluid were analysed. Ambroxol significantly suppressed virus multiplication and improved the survival rate of mice. The effect of ambroxol reached a peak at 10 mg x kg(-1) x day(-1), higher doses being less effective. Ambroxol stimulated the release of suppressors of influenza-virus multiplication, such as pulmonary surfactant, mucus protease inhibitor, immunoglobulin (Ig)-A and IgG, although it stimulated the release of a trypsin-type protease that potentiates virus proliferation. In addition, ambroxol transiently suppressed release of the cytokines, tumour necrosis factor-alpha, interferon-gamma and interleukin-12, into airway fluid. Although ambroxol had several negative effects on the host defence system, overall it strikingly increased the concentrations of suppressors of influenza-virus multiplication in the airway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12030738     DOI: 10.1183/09031936.02.00253302

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  20 in total

1.  Ambroxol - Resurgence of an old molecule as an anti-inflammatory agent in chronic obstructive airway diseases.

Authors:  P R Gupta
Journal:  Lung India       Date:  2010-04

2.  Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease.

Authors:  Gustavo H B Maegawa; Michael B Tropak; Justin D Buttner; Brigitte A Rigat; Maria Fuller; Deepangi Pandit; Liangiie Tang; Gregory J Kornhaber; Yoshitomo Hamuro; Joe T R Clarke; Don J Mahuran
Journal:  J Biol Chem       Date:  2009-07-03       Impact factor: 5.157

3.  A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs.

Authors:  Fu Shi Quan; David Steinhauer; Chunzi Huang; Ted M Ross; Richard W Compans; Sang-Moo Kang
Journal:  Vaccine       Date:  2008-04-11       Impact factor: 3.641

Review 4.  Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges.

Authors:  Ismail Sami Mahmoud; Yazun Bashir Jarrar
Journal:  Mol Biol Rep       Date:  2021-05-22       Impact factor: 2.316

5.  The protective effects of Ambroxol in Pseudomonas aeruginosa-induced pneumonia in rats.

Authors:  Xiwen Gao; Yi Huang; Yipin Han; Chun-Xue Bai; Guifang Wang
Journal:  Arch Med Sci       Date:  2011-07-11       Impact factor: 3.318

6.  Diisopropylamine dichloroacetate, a novel pyruvate dehydrogenase kinase 4 inhibitor, as a potential therapeutic agent for metabolic disorders and multiorgan failure in severe influenza.

Authors:  Kazuhiko Yamane; Irene L Indalao; Junji Chida; Yoshikazu Yamamoto; Masaaki Hanawa; Hiroshi Kido
Journal:  PLoS One       Date:  2014-05-27       Impact factor: 3.240

7.  Respiratory Viral Infections and Subversion of Cellular Antioxidant Defenses.

Authors:  Narayana Komaravelli; Antonella Casola
Journal:  J Pharmacogenomics Pharmacoproteomics       Date:  2014-09-30

Review 8.  Multi-Omics Studies towards Novel Modulators of Influenza A Virus-Host Interaction.

Authors:  Sandra Söderholm; Yu Fu; Lana Gaelings; Sergey Belanov; Laxman Yetukuri; Mikhail Berlinkov; Anton V Cheltsov; Simon Anders; Tero Aittokallio; Tuula A Nyman; Sampsa Matikainen; Denis E Kainov
Journal:  Viruses       Date:  2016-09-29       Impact factor: 5.048

9.  Ambroxol for the treatment of fibromyalgia: science or fiction?

Authors:  Kai-Uwe Kern; Myriam Schwickert
Journal:  J Pain Res       Date:  2017-08-16       Impact factor: 3.133

10.  Inhibition of inflammatory responses by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide.

Authors:  Xiao Su; Ling Wang; Yuanlin Song; Chunxue Bai
Journal:  Intensive Care Med       Date:  2003-09-20       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.